Does Humana Cover Mounjaro?

Humana Commercial Coverage for Mounjaro

Most Humana commercial (employer-sponsored and individual marketplace) plans include Mounjaro on their formulary for the FDA-approved indication of type 2 diabetes. The drug sits on a non-preferred brand or specialty tier in most plan documents, which translates to higher out-of-pocket costs than preferred generics like metformin. Prior authorization is required on virtually every Humana commercial plan.

Tirzepatide is a dual GIP and GLP-1 receptor agonist that the FDA approved in May 2022 for glycemic control in adults with type 2 diabetes. In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.58% from baseline compared with 1.86% for semaglutide 1 mg at 40 weeks. The same trial reported mean body weight reductions of 12.4 kg with the highest tirzepatide dose versus 6.2 kg with semaglutide [1]. These outcomes drove rapid formulary uptake, but insurers still gate access behind utilization management tools.

Humana's commercial pharmacy benefit typically requires prescribers to document a current HbA1c of 7.0% or higher and confirm that the patient has tried or has a contraindication to metformin. Some plans add a second step: evidence of inadequate control on a sulfonylurea or SGLT2 inhibitor. Coverage determination letters are usually issued within 72 hours of submission, though urgent requests can be expedited to 24 hours.

Formulary Tier and Cost With Humana

Mounjaro typically falls on Tier 4 (non-preferred specialty) or Tier 5 (specialty) across Humana commercial formularies, meaning coinsurance rather than a flat copay often applies. Patients on a Tier 4 plan might owe 25-40% coinsurance after their deductible, which at a list price of $1,023 per month could mean $250 to $410 per fill.

The exact tier placement varies by plan year and employer contract. Humana publishes its formulary search tool online, and members can verify their specific tier by entering "tirzepatide" or "Mounjaro" in the drug lookup. Pharmacy benefit managers renegotiate rebate agreements annually, so tier placement may shift at the start of each plan year.

For context, the American Diabetes Association's Standards of Care (2024) recommend GLP-1 receptor agonists as second-line therapy after metformin in patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, or when weight management is a treatment priority [2]. This guideline positioning supports medical necessity arguments during prior authorization.

Patients who face high coinsurance should ask their prescriber's office about the Lilly Mounjaro Savings Card. Commercially insured patients with a valid prescription for an FDA-approved indication may pay as little as $25 per monthly fill, with a maximum annual benefit that Lilly periodically adjusts. The savings card cannot be used with government insurance programs, including Medicare, Medicaid, or Tricare.

Prior Authorization: What Humana Requires

Humana's prior authorization for Mounjaro follows a clinical criteria checklist. Approval is not automatic. The prescriber must demonstrate medical necessity through documentation submitted to Humana's pharmacy benefit manager.

Standard criteria across most Humana commercial plans include: a confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x), a recent HbA1c lab result (typically drawn within the past 90 days), documentation that the patient has tried metformin for at least 90 days or has a documented contraindication such as an eGFR below 30 mL/min/1.73m², and a statement from the prescriber explaining why tirzepatide is the appropriate next step. Some plans require a trial or documented intolerance to at least one other GLP-1 receptor agonist, such as semaglutide or dulaglutide, before approving tirzepatide specifically.

The Endocrine Society's 2022 clinical practice guideline on pharmacologic management of obesity supports the use of GLP-1 receptor agonists in patients with BMI of 30 kg/m² or higher, or 27 kg/m² with weight-related comorbidities [3]. While this guideline addresses obesity management rather than diabetes, it can supplement a prior authorization submission when a patient with type 2 diabetes also has significant obesity, strengthening the clinical rationale.

Processing timelines vary. Standard requests are decided within 72 hours. Urgent or expedited requests, which a prescriber can flag when a delay could cause serious harm, must be resolved within 24 hours under Humana's internal policies.

Step Therapy Requirements on Humana Plans

Humana frequently applies step therapy protocols to Mounjaro, requiring patients to "fail" one or more lower-cost medications before gaining access. This is standard practice across most large insurers for GLP-1 receptor agonists and dual agonists.

The most common first step is metformin. Humana generally requires 90 days of metformin therapy at a maximally tolerated dose, or documented intolerance (gastrointestinal side effects are the most frequent reason for discontinuation). After the metformin step, some Humana plans impose a second step: a trial of a sulfonylurea, an SGLT2 inhibitor, or a lower-cost GLP-1 receptor agonist. This second step requirement has become more common as plan sponsors seek to control specialty drug spending.

The step therapy requirement can be bypassed in specific clinical scenarios. Patients with stage 3b or worse chronic kidney disease (eGFR <45 mL/min/1.73m²) may be exempt from the metformin step because metformin carries a labeled precaution at reduced renal function thresholds. Patients with a documented history of lactic acidosis on metformin also qualify for an exemption. Prescribers should document these exceptions clearly in the prior authorization submission.

A 2023 analysis published in Diabetes Care noted that early initiation of GLP-1 receptor agonists in patients with high cardiovascular risk may reduce major adverse cardiovascular events, a point that can support step therapy override requests when the patient's risk profile warrants aggressive early intervention [4].

Humana Medicare Advantage and Mounjaro

Medicare Advantage coverage for Mounjaro is significantly more restrictive than commercial coverage. This is a direct consequence of federal policy, not a Humana-specific decision.

The Centers for Medicare & Medicaid Services (CMS) has historically excluded drugs used for "anorexia, weight loss, or weight gain" from Medicare Part D coverage under Section 1862(a)(1)(A) of the Social Security Act. While Mounjaro holds an FDA-approved indication for type 2 diabetes (not weight loss), Medicare Advantage plans administered by Humana will cover tirzepatide only for the diabetes indication. If a prescriber submits a prior authorization citing weight management as the primary goal, the claim will be denied.

For Humana Medicare Advantage members with type 2 diabetes, coverage is available but requires prior authorization demonstrating the diabetes indication. The CDC's National Diabetes Statistics Report (2022) estimates that 29.2% of adults aged 65 and older have diagnosed diabetes [5], making this a substantial population segment that may qualify.

Dr. Robert Gabbay, Chief Science and Medical Officer of the American Diabetes Association, has stated: "Access to newer therapies like GLP-1 receptor agonists and dual agonists is a clinical priority for patients with type 2 diabetes who are not reaching glycemic targets on older agents." This perspective underscores the tension between cost-containment policies and guideline-driven care.

Medicare Advantage denials can be appealed through a specific pathway. The first step is an internal Humana redetermination. If denied again, the case moves to an Independent Review Entity (IRE), which for Medicare Part D is currently operated by MAXIMUS Federal Services. The timeline for a standard redetermination is 7 calendar days; an expedited request must be resolved within 72 hours.

How to Appeal a Humana Denial for Mounjaro

A denial does not mean final rejection. Humana members have the right to appeal, and success rates for well-documented appeals are meaningful.

Start with the denial letter. Every Humana denial includes a specific reason code and a citation to the coverage criteria the claim failed to meet. Read this carefully. The most common denial reasons for Mounjaro are: step therapy not completed, insufficient documentation of diagnosis, HbA1c not meeting threshold, or off-label use for weight loss without a diabetes diagnosis.

The first-level appeal is an internal reconsideration submitted to Humana. Include updated clinical documentation that directly addresses the stated denial reason. If the denial cited incomplete step therapy, attach pharmacy claims or prescriber notes documenting the prior medication trials and their outcomes. A letter of medical necessity from the prescribing physician that references ADA Standards of Care guidelines significantly strengthens the appeal [6].

For commercial plans, if the internal appeal is denied, Humana members can request an external review through their state's independent review organization. The external reviewer is a physician not affiliated with Humana who evaluates the clinical evidence independently. External reviews overturn insurer denials in roughly 40-50% of cases across all drug classes, according to data compiled by state insurance departments.

For Medicare Advantage members, the appeal pathway after internal denial routes through MAXIMUS (the CMS-contracted IRE), then to an Administrative Law Judge if the amount in controversy meets the annual threshold (currently $190 for 2026). Each level has specific filing deadlines. Missing these deadlines forfeits the appeal right for that level.

The American Medical Association's prior authorization reform principles call for real-time electronic decisions, a position echoed by the Endocrine Society's advocacy statements. Patients frustrated by repeated denials can also file complaints with their state insurance commissioner, which creates a regulatory record even if it does not reverse the specific denial.

Off-Label Weight Loss Coverage Through Humana

Humana does not cover Mounjaro for weight loss on most plans because tirzepatide under the Mounjaro brand carries an FDA indication only for type 2 diabetes. Eli Lilly markets the same molecule as Zepbound for chronic weight management, and coverage policies differ between the two brand names even though the active ingredient is identical.

The SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks in adults with obesity or overweight without diabetes, compared with 2.4% for placebo [7]. These results led to the FDA approval of Zepbound in November 2023 for chronic weight management. Humana's coverage of Zepbound is governed by a separate policy and is not available on most Medicare Advantage plans due to the CMS weight-loss drug exclusion.

For Humana commercial members, some employer-sponsored plans have added obesity medication coverage as an optional benefit rider. Patients should check whether their specific plan includes this rider by calling the number on the back of their insurance card or reviewing their Summary of Benefits and Coverage document. Even when the rider exists, prior authorization is required, and BMI must typically be 30 kg/m² or higher (or 27 kg/m² with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea).

Manufacturer Savings Card and Patient Assistance

Eli Lilly's Mounjaro Savings Card program offers commercially insured patients potential out-of-pocket reductions. Eligible patients pay as little as $25 per monthly prescription for up to 12 pens per calendar month, subject to annual benefit maximums that Lilly revises periodically.

Eligibility requirements include: a valid prescription for an FDA-approved use, commercial insurance (not government-funded), and U.S. residency. Patients without any insurance or with government insurance do not qualify for the savings card but may apply for the Lilly Patient Assistance Program, which provides Mounjaro at no cost to qualifying individuals earning below 400% of the federal poverty level.

A 2022 analysis in JAMA Internal Medicine found that manufacturer copay assistance programs, while reducing short-term patient costs, can sometimes delay therapeutic alternatives when the savings card expires or when the patient transitions to a plan that does not cover the medication [8]. Patients should plan for what happens after the savings card benefit is exhausted.

For Humana members specifically, the savings card can be applied at the pharmacy as a secondary payer after Humana processes the claim. The pharmacy applies the Humana benefit first, then the savings card covers remaining eligible out-of-pocket costs up to its limit. Not all pharmacies process secondary manufacturer cards automatically; patients may need to present both cards and ask the pharmacist to run a coordination of benefits.

Comparing Humana's Mounjaro Policy to Other Major Insurers

Humana's coverage posture on Mounjaro is broadly consistent with other large national carriers. Prior authorization is universal. Step therapy through metformin is the norm. The differences tend to be in specifics: how many prior agents are required, whether a second GLP-1 receptor agonist trial is mandatory before tirzepatide, and the coinsurance percentage applied at the formulary tier.

According to formulary data published by CMS for Medicare Part D plans, tirzepatide appeared on fewer than 60% of Medicare Part D formularies in the 2025 plan year, with quantity limits and prior authorization applied on nearly every plan that included it [9]. Humana's Medicare Advantage drug coverage tracks closely with these national patterns.

The ADA's 2024 Standards of Care explicitly state: "Cost and insurance coverage should be considered when selecting glucose-lowering medications, but should not be the sole determinant of therapy choice when clinical evidence supports a specific agent" [6]. This language from the ADA can be cited in appeals and prior authorization requests when Humana's formulary restrictions limit access to a clinically indicated therapy.

Patients switching from another insurer to Humana mid-year should request a transition supply. Humana is required to provide at least a 30-day transition fill for enrollees who were stabilized on a medication covered by their prior plan but not on the new Humana formulary, under CMS transition of care regulations for Medicare plans and similar state-level protections for commercial plans.